Vicapsys Life Sciences, Inc. (VICP)
USD 1.77
(39.37%)
USD 1.77
(39.37%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.04 Million USD | 62.43% |
| 2022 | 644.55 Thousand USD | 91.34% |
| 2021 | 336.87 Thousand USD | -56.01% |
| 2020 | 765.84 Thousand USD | -25.93% |
| 2019 | 1.03 Million USD | -10.7% |
| 2018 | 1.15 Million USD | -62.11% |
| 2017 | 3.05 Million USD | 0.0% |
| 2009 | 1.89 Million USD | -14.44% |
| 2008 | 2.21 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q4 | 527.2 Thousand USD | 200.53% |
| 2023 Q1 | 211.27 Thousand USD | 38.66% |
| 2023 Q3 | 175.42 Thousand USD | 29.28% |
| 2023 Q2 | 135.69 Thousand USD | -35.77% |
| 2022 FY | 644.55 Thousand USD | 91.34% |
| 2022 Q2 | 180.05 Thousand USD | 7.79% |
| 2022 Q3 | 145.08 Thousand USD | -19.42% |
| 2022 Q4 | 152.37 Thousand USD | 5.03% |
| 2022 Q1 | 167.04 Thousand USD | 60.84% |
| 2021 Q2 | 72.06 Thousand USD | 44.79% |
| 2021 FY | 336.87 Thousand USD | -56.01% |
| 2021 Q4 | 103.85 Thousand USD | -6.59% |
| 2021 Q3 | 111.18 Thousand USD | 54.29% |
| 2021 Q1 | 49.77 Thousand USD | -38.21% |
| 2020 Q3 | 89.22 Thousand USD | -61.48% |
| 2020 Q2 | 231.61 Thousand USD | -36.45% |
| 2020 FY | 765.84 Thousand USD | -25.93% |
| 2020 Q1 | 364.45 Thousand USD | 46.0% |
| 2020 Q4 | 80.54 Thousand USD | -9.72% |
| 2019 Q2 | 151.34 Thousand USD | -7.49% |
| 2019 FY | 1.03 Million USD | -10.7% |
| 2019 Q4 | 249.63 Thousand USD | -46.81% |
| 2019 Q3 | 469.34 Thousand USD | 210.12% |
| 2019 Q1 | 163.59 Thousand USD | 95.08% |
| 2018 Q4 | 83.85 Thousand USD | 0.0% |
| 2018 FY | 1.15 Million USD | -62.11% |
| 2017 FY | 3.05 Million USD | 0.0% |
| 2010 Q1 | 429.53 Thousand USD | 19156.67% |
| 2010 Q2 | 1.14 Million USD | 165.77% |
| 2009 FY | 1.89 Million USD | -14.44% |
| 2009 Q4 | 2230.56 USD | 0.0% |
| 2009 Q2 | 508.08 Thousand USD | 17.82% |
| 2009 Q1 | 431.24 Thousand USD | 0.0% |
| 2008 FY | 2.21 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -58.337% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | 88.703% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | 96.509% |
| Biora Therapeutics, Inc. | 67.14 Million USD | 98.441% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | 93.392% |
| Better Therapeutics, Inc. | 38.26 Million USD | 97.264% |
| Calithera Biosciences, Inc. | 40.68 Million USD | 97.427% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | 91.552% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | 96.906% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | 96.958% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 99.035% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -5.456% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | 96.787% |
| Galera Therapeutics, Inc. | 46.95 Million USD | 97.77% |
| Innovation1 Biotech Inc. | 1.21 Million USD | 13.807% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | 94.749% |
| Molecular Templates, Inc. | 63.09 Million USD | 98.341% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | 92.485% |
| NexImmune, Inc. | 28.16 Million USD | 96.283% |
| Orgenesis Inc. | 45.75 Million USD | 97.712% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | 95.918% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -1326.09% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | 93.515% |
| Scopus BioPharma Inc. | 11.71 Million USD | 91.063% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 99.741% |
| Statera Biopharma, Inc. | 28.82 Million USD | 96.368% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | 94.469% |
| Trevena, Inc. | 38.41 Million USD | 97.274% |
| Vaxxinity, Inc. | 56.05 Million USD | 98.132% |
| Vaccinex, Inc. | 23.45 Million USD | 95.536% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | 97.935% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | 85.608% |